Literature DB >> 9291804

Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone.

A Horwich1, L Specht, S Ashley.   

Abstract

To aid treatment choice in early stage of Hodgkin's disease, we analysed patients registered in the IDHD Database with clinical stages I or II Hodgkin's disease who were not staged with laparotomy and whose initial treatment was with radiotherapy alone. The factors analysed for outcome after first relapse included initial stage, age, sex, histology, number of involved areas, mediastinal involvement, E-lesions, B-symptoms, erythrocyte sedimentation rate, alkaline phosphatase, serum albumin and haemoglobin. As well as presentation variables, we analysed the disease-free interval after initial radiotherapy and the extent of disease at relapse. A total of 1364 patients with clinical stage I or II Hodgkin's disease were treated with initial radiotherapy, of whom 473 relapsed. The probability of survival 10 years after relapse was 63%. For cause-specific survival (CSS), both multivariate and univariate analysis identified the importance of age at presentation and histological subtypes. When all causes of death were considered, the multivariate analysis identified age as the only significant factor. The length of initial disease-free interval had no influence on prognosis after relapse, but the 169 patients with nodal relapse had a higher cause-specific survival than those with an extranodal component of relapse (74% versus 51% at 10 years, P < 0.005). Thus, the important factors for outcome after initial treatment with radiotherapy are those factors predicting the risk of relapse after initial treatment together with those predicting outcome after relapse, namely age, histologic subtype and extent of disease at relapse.

Entities:  

Mesh:

Year:  1997        PMID: 9291804     DOI: 10.1016/s0959-8049(96)00518-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

Review 1.  Early-stage Hodgkin's disease.

Authors:  A Josting; V Diehl
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

Review 2.  State of the art in the treatment of Hodgkin lymphoma.

Authors:  Peter Borchmann; Dennis A Eichenauer; Andreas Engert
Journal:  Nat Rev Clin Oncol       Date:  2012-06-12       Impact factor: 66.675

Review 3.  First-line treatment of Hodgkin's lymphoma.

Authors:  Beate Klimm; Andreas Engert; Volker Diehl
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 3.952

Review 4.  The GHSG Approach to Treating Hodgkin's Lymphoma.

Authors:  Paul J Bröckelmann; Andreas Engert
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

5.  Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group.

Authors:  Kavita V Dharmarajan; Debra L Friedman; Cindy L Schwartz; Lu Chen; T J FitzGerald; Kathleen M McCarten; Sandy K Kessel; Matt Iandoli; Louis S Constine; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-12-24       Impact factor: 7.038

Review 6.  [Modern pharmacotherapy of Hodgkin disease].

Authors:  A Josting; K Behringer; A Engert; V Diehl
Journal:  Internist (Berl)       Date:  2004-01       Impact factor: 0.743

7.  Current treatment strategies in early stage Hodgkin's disease.

Authors:  Andreas Josting; Volker Diehl
Journal:  Curr Treat Options Oncol       Date:  2003-08

Review 8.  Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion.

Authors:  Adarsh Sidda; Nikolas Kristopher Naleid; Gurusidda Manu; Vincent Graffeo; Muhammad Omer Jamil
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec

9.  Overview and outcome of Hodgkin's Lymphoma: Experience of a single developing country's oncology centre.

Authors:  Rawand P Shamoon; Mohamad Dahir Ali; Nazar P Shabila
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.